These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
576 related articles for article (PubMed ID: 16809439)
1. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Lupu R; Menendez JA Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777 [TBL] [Abstract][Full Text] [Related]
3. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544 [TBL] [Abstract][Full Text] [Related]
4. Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells. Menendez JA; Lupu R Oncogenesis; 2017 Feb; 6(2):e299. PubMed ID: 28240737 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Vazquez-Martin A; Colomer R; Brunet J; Menendez JA Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307 [TBL] [Abstract][Full Text] [Related]
6. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Menendez JA; Vellon L; Lupu R Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499 [TBL] [Abstract][Full Text] [Related]
7. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer. Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K Oncology; 2013; 84(3):166-73. PubMed ID: 23306391 [TBL] [Abstract][Full Text] [Related]
8. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene. Menendez JA; Vellon L; Oza BP; Lupu R J Cell Biochem; 2005 Apr; 94(5):857-63. PubMed ID: 15669079 [TBL] [Abstract][Full Text] [Related]
9. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Menendez JA; Ropero S; Mehmi I; Atlas E; Colomer R; Lupu R Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577 [TBL] [Abstract][Full Text] [Related]
10. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Menendez JA; Lupu R Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825 [TBL] [Abstract][Full Text] [Related]
11. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855 [TBL] [Abstract][Full Text] [Related]
12. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509 [TBL] [Abstract][Full Text] [Related]
13. Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. Singleton DW; Feng Y; Burd CJ; Khan SA Endocrinology; 2003 Jan; 144(1):121-8. PubMed ID: 12488337 [TBL] [Abstract][Full Text] [Related]
14. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Menendez JA; Oza BP; Colomer R; Lupu R Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863 [TBL] [Abstract][Full Text] [Related]
15. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Lupu R; Menendez JA Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Wang Z; Kyo S; Maida Y; Takakura M; Tanaka M; Yatabe N; Kanaya T; Nakamura M; Koike K; Hisamoto K; Ohmichi M; Inoue M Oncogene; 2002 May; 21(22):3517-24. PubMed ID: 12032853 [TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. Menendez JA; Vellon L; Lupu R Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011 [TBL] [Abstract][Full Text] [Related]